A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
暂无分享,去创建一个
N. Zaffaroni | A. Anichini | M. Di Nicola | D. Mezzanzanica | A. Gianni | M. Figini | F. Caroli | F. Raspagliesi | G. Grazia | B. Frigerio | A. Satta
[1] S. Canevari,et al. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells , 2018, mAbs.
[2] H. Walczak,et al. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.
[3] C. Klein,et al. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. , 2017, Cancer cell.
[4] Thomas D. Wu,et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.
[5] W. Lim,et al. The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.
[6] Chao Lu,et al. Retrospective study , 2016, Medicine.
[7] G. Sethi,et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy , 2015, Experimental biology and medicine.
[8] M. Sanford. Blinatumomab: First Global Approval , 2015, Drugs.
[9] S. Canevari,et al. Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma , 2014, Cell Death and Disease.
[10] B. Aggarwal,et al. Targeting death receptors for TRAIL by agents designed by Mother Nature. , 2014, Trends in pharmacological sciences.
[11] M. Provenzano,et al. Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen receptors. , 2013, Recent patents on anti-cancer drug discovery.
[12] A. Dafopoulos,et al. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature , 2013, Archives of Gynecology and Obstetrics.
[13] S. Canevari,et al. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. , 2013, Future oncology.
[14] スティーブン ジェイ. ブレイクモア,,et al. How to treat cancer , 2013 .
[15] R. Angioli,et al. HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[16] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[17] H. Pircher,et al. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. , 2010, Cancer research.
[18] P. Murawa,et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.
[19] Mark J. Smyth,et al. The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.
[20] R. Herbst,et al. To kill a tumor cell: the potential of proapoptotic receptor agonists. , 2008, The Journal of clinical investigation.
[21] S. Parsons,et al. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] F. Cordelières,et al. A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.
[23] G. Screaton,et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues , 2005, Cell Research.
[24] A. Anichini,et al. Apoptosis Protease Activator Protein-1 Expression Is Dispensable for Response of Human Melanoma Cells to Distinct Proapoptotic Agents , 2004, Cancer Research.
[25] A. Ashkenazi,et al. Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.
[26] J. Kilpatrick,et al. High affinity ScFvs from a single rabbit immunized with multiple haptens. , 2000, Biochemical and biophysical research communications.
[27] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[28] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[29] R. Martin,et al. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. , 1994, Journal of immunological methods.
[30] A. Nicolin,et al. CLONAL ANALYSIS OF T LYMPHOCYTES ISOLATED FROM OVARIAN CARCINOMA ASCITIC FLUID. PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF T‐CELL CLONES CAPABLE OF LYSING AUTOLOGOUS CARCINOMA CELLS , 1985, International journal of cancer.
[31] U. Brinkmann,et al. Bispecific antibodies. , 2015, Drug discovery today.
[32] C. Rancourt,et al. Targeted ovarian cancer treatment: the TRAILs of resistance. , 2012, American journal of cancer research.
[33] A. R.,et al. Review of literature , 1960, American Potato Journal.
[34] A. Ashkenazi,et al. Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.
[35] A. Lanzavecchia,et al. The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.